The metered dose inhalers market was expected to be valued at US$ 25,208.9 million in 2022, and it is projected to reach US$ 26,322.9 million in 2023. As per the Future Market Research report, this market is anticipated to exhibit a compound annual growth rate (CAGR) of 4.5% from 2023 to 2033, ultimately reaching an estimated total value of approximately US$ 40,895.5 million by 2033.
Metered Dose Inhalers have the added advantage of being capable of multidose delivery capacity, being simple to use, and being at a lower risk of contamination through bacteria (being prefilled).
Digital dose inhalers are amongst the trendy products available as of now and the status quo is expected to remain the same even in the forecast period. This could be credited to the fact that they do deliver a prescribed quantity of medication to the lungs in the form of dry powder or aerosolized medicine.
Get Your Sample Report to learn about recent in the Metered Dose Inhalers industry observed by FMI
https://www.futuremarketinsights.com/reports/sample/rep-gb-5308
At the same time, the fact that there is a sizable lack of awareness amongst the population regarding advanced treatment and devices available for asthma. This, in turn, is somewhat discouraging for the market participants to extend their research toward the under-developed economies. Additionally, the manufacturing cost for metered doses is quite high. They could also end up having side-effects. These factors are likely to restrain the Metered Dose Inhalers market in the years to come. Future Market Insights has etched these findings with future perspectives in its latest market study entitled ‘Metered Dose Inhalers Market’. It has its line of expertise in the form of analysts and consultants to execute.
“With realization of the fact that Metered Dose Inhalers are subject to simple application, the global Metered Dose Inhalers market is bound to go great guns going forward, says an analyst from Future Market Insights.
Key Takeaways from the Metered Dose Inhalers Market
- North America holds the largest market (over 40%) share due to extensive research being conducted on the count of respiratory disorders and treatments pertaining to the same.
- Europe stands second with more than 25% of the market share due to the reasons mentioned above.
- The Asia-Pacific is expected to grow at the fastest rate in the Metered Dose Inhalers market going forward due to conducive initiatives undertaken by the governments herein.
Competitive Analysis
- Propeller Health, in 2019, did launch ‘Diskus’. It’s used for controlling and preventing symptoms like shortness of breath and wheezing resulting out of asthma and COPD, which include emphysema and chronic bronchitis.
- Novartis has its ‘Symbicort’. The inhaler is actually used for controlling and preventing symptoms pertaining to asthma in children aged 6 and below and also adults. It’s used for addressing emphysema and chronic bronchitis.
- Glenmark Pharmaceuticals Ltd. holds the distinction of launching India’s very first digital dose inhaler called ‘Digihaler’ for those affected by pulmonary diseases and asthma.
- Teva Pharmaceutical Industries Ltd., in 2019, did announce that its inhalation powder ‘ProAir Digihaler’ was approved by the US FDA. It’s the sole digital inhaler containing built-in sensors that gets connected to companion mobile application and informs people with COPD and asthma. Digihaler could effectively treat/prevent bronchospasm and also EIB (exercise-induced bronchospasm) in those aged 4 and above.
- Honeywell, in February 2022, entered into partnership with Astrazeneca for developing next-generation respiratory inhalers by making use of propellant HFO-1234ze. It has got99.9% less potential of global warming as compared to the propellants used at the moment.
- Aptar Pharma, in February 2022, tabled HeroTracker Sense. It’s a new digital respiratory health solution transforming a proper metered dose inhaler into smart connected healthcare device.
- NuvoAir, in December 2021, came up with an add-on sensor for COPD and asthma inhalers as an integrated part of chronic care ecosystem.
Contact Sales for Further Assistance in Purchasing this Report
https://www.futuremarketinsights.com/checkout/5308
Key Players in the Metered Dose Inhalers Market
Cipla Inc., Presspart Manufacturing Ltd., Midascare Pharmaceuticals Pvt. Ltd., Beximco Pharma Ltd., GlaxoSmithKline Pharmaceuticals Ltd., 3M Pharmaceuticals Pty Ltd., Biocare Manufacturing Sdn Bhd, Anomatic Innovation & Design Center & Manufacturing, Aristo Pharma Ltd, Intech Biopharm Corporation, Swiss Pharmaceuticals Pvt. Ltd and others.
Key Segments
By Type:
- Preventive Inhale
- Reliever Inhaler
- Long-Acting Bronchodilators Inhaler
- By Application
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
By End-User:
- Homecare
- Hospitals
- Clinics
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Nandini Singh Sawlani
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
